Comerica Bank Bristol Myers Squibb CO Transaction History

Comerica Bank

$25 Billion
Q3 2024

A detailed history of Comerica Bank transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Comerica Bank holds 722,237 shares of BMY stock, worth $42.1 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares

722,237

Previous 687,085 5.12%

Holding current value

$42.1 Million

Previous $28.5 Million 30.98%

% of portfolio

0.15%

Previous 0.12%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$39.66 - $51.75 $1.39 Million - $1.82 Million	35,152 Added 5.12%	722,237 $37.4 Million
Q2 2024 Aug 15, 2024	SELL	$40.25 - $52.99 $1.34 Million - $1.76 Million	-33,220 Reduced 4.61%	687,085 $28.5 Million
Q1 2024 May 15, 2024	BUY	$47.98 - $54.4 $1.23 Million - $1.4 Million	25,716 Added 3.7%	720,305 $39.1 Million
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $2.63 Million - $3.14 Million	-54,233 Reduced 7.24%	694,589 $35.6 Million
Q3 2023 Nov 21, 2023	BUY	$57.89 - $64.73 $21.2 Million - $23.8 Million	367,044 Added 96.14%	748,822 $43.5 Million
Q2 2023 Aug 22, 2023	SELL	$63.71 - $70.74 $8.73 Million - $9.7 Million	-137,079 Reduced 26.42%	381,778 $99,000
Q4 2022 Jan 26, 2023	BUY	$68.48 - $81.09 $159,079 - $188,372	2,323 Added 0.45%	518,857 $0
Q3 2022 Oct 28, 2022	BUY	$0.13 - $76.84 $677 - $400,566	5,213 Added 1.02%	516,534 $37.7 Million
Q2 2022 Aug 02, 2022	SELL	$72.62 - $79.98 $1.22 Million - $1.34 Million	-16,735 Reduced 3.17%	511,321 $37.4 Million
Q1 2022 Apr 27, 2022	BUY	$61.48 - $73.72 $278,197 - $333,583	4,525 Added 0.86%	528,056 $38.6 Million
Q4 2021 Feb 18, 2022	BUY	$53.63 - $62.52 $482,187 - $562,117	8,991 Added 1.75%	523,531 $32.6 Million
Q3 2021 Nov 22, 2021	SELL	$59.17 - $69.31 $4.4 Million - $5.15 Million	-74,279 Reduced 12.61%	514,540 $30.4 Million
Q2 2021 Aug 26, 2021	SELL	$61.91 - $67.42 $2.49 Million - $2.71 Million	-40,142 Reduced 6.38%	588,819 $39.3 Million
Q1 2021 Apr 28, 2021	SELL	$59.34 - $66.74 $1.64 Million - $1.85 Million	-27,709 Reduced 4.22%	628,961 $39.7 Million
Q4 2020 Jan 28, 2021	SELL	$57.74 - $65.43 $1.57 Million - $1.77 Million	-27,106 Reduced 3.96%	656,670 $40.7 Million
Q3 2020 Oct 30, 2020	BUY	$57.43 - $63.64 $517,272 - $573,205	9,007 Added 1.33%	683,776 $41.2 Million
Q2 2020 Jul 31, 2020	BUY	$54.82 - $64.09 $2.14 Million - $2.5 Million	38,955 Added 6.13%	674,769 $39.7 Million
Q1 2020 May 01, 2020	SELL	$46.4 - $67.43 $683,564 - $993,378	-14,732 Reduced 2.26%	635,814 $35.4 Million
Q4 2019 Feb 07, 2020	BUY	$49.21 - $64.19 $6.29 Million - $8.21 Million	127,843 Added 24.46%	650,546 $41.8 Million
Q3 2019 Oct 31, 2019	BUY	$42.77 - $50.71 $143,707 - $170,385	3,360 Added 0.65%	522,703 $26.5 Million
Q2 2019 Aug 02, 2019	SELL	$44.62 - $49.34 $36,409 - $40,261	-816 Reduced 0.16%	519,343 $0
Q1 2019 May 02, 2019	BUY	$45.12 - $53.8 $458,825 - $547,092	10,169 Added 1.99%	520,159 $0
Q4 2018 Feb 06, 2019	SELL	$48.76 - $63.23 $157,787 - $204,612	-3,236 Reduced 0.63%	509,990 $24.6 Million
Q3 2018 Nov 01, 2018	SELL	$55.19 - $62.25 $4.72 Million - $5.33 Million	-85,565 Reduced 14.29%	513,226 $26 Million
Q2 2018 Aug 01, 2018	SELL	$50.53 - $62.98 $362,451 - $451,755	-7,173 Reduced 1.18%	598,791 $33.9 Million
Q1 2018 May 01, 2018	SELL	$59.92 - $68.98 $621,190 - $715,115	-10,367 Reduced 1.68%	605,964 $31.3 Million
Q4 2017 Feb 02, 2018	SELL	$59.94 - $65.35 $185,094 - $201,800	-3,088 Reduced 0.5%	616,331 $39.3 Million
Q3 2017 Nov 06, 2017	BUY	$55.23 - $63.74 $34.2 Million - $39.5 Million	619,419	619,419 $37.7 Million

Others Institutions Holding BMY

# of Institutions

2,533

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $124B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

News

Stay updated on Comerica Bank with notifications on news.

Account